Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chapman

Showing results (61-70 of 320) with videos related to

Pageof 32
Sort By:
Biofactors (Oxford, England)|March 27, 2015
HDL particle subpopulations: Focus on biological functionFabiana H Rached, M John Chapman, Anatol Kontush
Psychiatric Services (Washington, D.C.)|January 2, 2003
Crisis intervention services in juvenile detention centersCharles A Sanislow, John Chapman, Thomas H McGlashan
Rheumatology (Oxford, England)|August 31, 2011
Lumbar canal spinal stenosis due to axial skeletal calcinosis and heterotopic ossification in limited cutaneous systemic sclerosis: successful spinal decompressionAnita Weerakoon, David Sharp, John Chapman, et al.
Journal of Clinical Lipidology|August 21, 2019
PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroadsLieven Annemans, Jane K Stock, M John Chapman
European Heart Journal|March 14, 2013
The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITERM John Chapman, Philippe Giral, Philip J Barter
Journal of the American College of Cardiology|January 29, 2025
Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With CautionChris J Packard, Jan Borén, M John Chapman
Pharmacology & Therapeutics|January 20, 2004
Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemiaWilfried Le Goff, Maryse Guerin, M John Chapman
Atherosclerosis|May 15, 2025
Editorial: The Brussels International Declaration on Lp(a) Testing And Management-A call to actionJan Borén, M John Chapman, Chris J Packard
Diabetes Care|January 30, 2007
Glucose measurement: confounding issues in setting targets for inpatient managementKathleen Dungan, John Chapman, Susan S Braithwaite, et al.
Cardiology Clinics|April 4, 2018
Impact of Lipoproteins on Atherobiology: Emerging InsightsMa Feng, Fabiana Rached, Anatol Kontush, et al.
Pageof 32

Showing results (61-70 of 320) with videos related to

Sort By:
Pageof 32
Biofactors (Oxford, England)|March 27, 2015
HDL particle subpopulations: Focus on biological functionFabiana H Rached, M John Chapman, Anatol Kontush
Psychiatric Services (Washington, D.C.)|January 2, 2003
Crisis intervention services in juvenile detention centersCharles A Sanislow, John Chapman, Thomas H McGlashan
Rheumatology (Oxford, England)|August 31, 2011
Lumbar canal spinal stenosis due to axial skeletal calcinosis and heterotopic ossification in limited cutaneous systemic sclerosis: successful spinal decompressionAnita Weerakoon, David Sharp, John Chapman, et al.
Journal of Clinical Lipidology|August 21, 2019
PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroadsLieven Annemans, Jane K Stock, M John Chapman
European Heart Journal|March 14, 2013
The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: insight from EPIC-Norfolk and JUPITERM John Chapman, Philippe Giral, Philip J Barter
Journal of the American College of Cardiology|January 29, 2025
Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With CautionChris J Packard, Jan Borén, M John Chapman
Pharmacology & Therapeutics|January 20, 2004
Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemiaWilfried Le Goff, Maryse Guerin, M John Chapman
Atherosclerosis|May 15, 2025
Editorial: The Brussels International Declaration on Lp(a) Testing And Management-A call to actionJan Borén, M John Chapman, Chris J Packard
Diabetes Care|January 30, 2007
Glucose measurement: confounding issues in setting targets for inpatient managementKathleen Dungan, John Chapman, Susan S Braithwaite, et al.
Cardiology Clinics|April 4, 2018
Impact of Lipoproteins on Atherobiology: Emerging InsightsMa Feng, Fabiana Rached, Anatol Kontush, et al.
Pageof 32